A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma.

Trial Profile

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 1 Jul 2012 to 1 Dec 2018.
    • 15 Feb 2017 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017.
    • 03 Feb 2012 Actual end date (December 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top